Clarius Group LLC’s Sana Biotechnology SANA Stock Holding History

Clarius Group LLC’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$676K	Sell	166,065 -46,435	-22%	-$208K	0.04%	163
2025 Q3	$754K	Hold	212,500	–	–	0.04%	156
2025 Q2	$580K	Hold	212,500	–	–	0.03%	224
2025 Q1	$357K	Buy	212,500 +100,000	+89%	+$280K	0.02%	305
2024 Q4	$183K	Buy	112,500 +49,316	+78%	+$147K	0.01%	434
2024 Q3	$263K	Hold	63,184	–	–	0.02%	349
2024 Q2	$345K	Buy	63,184 +16,359	+35%	+$130K	0.02%	290
2024 Q1	$468K	Hold	46,825	–	–	0.03%	236
2023 Q4	$191K	Hold	46,825	–	–	0.02%	461
2023 Q3	$181K	Hold	46,825	–	–	0.02%	442
2023 Q2	$279K	Hold	46,825	–	–	0.02%	410
2023 Q1	$153K	Hold	46,825	–	–	0.01%	489
2022 Q4	$185K	Buy	46,825 +34,325	+275%	+$168K	0.02%	486
2022 Q3	$75K	Hold	12,500	–	–	0.01%	478
2022 Q2	$80K	Hold	12,500	–	–	0.01%	460
2022 Q1	$194K	Hold	12,500	–	–	0.02%	476
2021 Q4	$194K	Hold	12,500	–	–	0.02%	476
2021 Q3	$282K	Hold	12,500	–	–	0.03%	330
2021 Q2	$246K	Buy	+12,500	New	+$283K	0.02%	353

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Clarius Group LLC's SANA Position: Q4 2025 in Review

Clarius Group LLC reduced its Sana Biotechnology (SANA) stake by 22% in Q4 2025, selling an estimated $208K and leaving 166,065 shares worth $676K. The position accounts for 0.04% of the portfolio, ranked #163.

Clarius Group LLC first reported a position in SANA in Q2 2021 and has held it in 19 quarters since. The position peaked at $754K in Q3 2025. 203 funds tracked by Wall St. Rank hold SANA as of Q4 2025.

Clarius Group LLC held 166,065 shares of Sana Biotechnology worth $676K as of Q4 2025.
Clarius Group LLC sold 46,435 Sana Biotechnology shares in Q4 2025, an estimated $208K.
Sana Biotechnology made up 0.04% of Clarius Group LLC's portfolio in Q4 2025, its #163 holding.
Clarius Group LLC first reported a position in Sana Biotechnology in Q2 2021 and has held it in 19 quarters since.
Clarius Group LLC's Sana Biotechnology position peaked at $754K in Q3 2025.
203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.